FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Anand Rathi, Ashika Research, Choice Equity Broking Pvt Ltd, Dolat Analysis and Research, GEPL Capital Ltd, ICICI Direct, Investmentz Ltd, Sushil Finance Ltd, InvestorGain.com and Ventura Securities Limited have given "Apply" recommendation to Glenmark Life Sciences IPO. Capital Market, Dilip Davda and SMC Global have given "May Apply" recommendation to Glenmark Life Sciences IPO. Axis Capital and HDFC Securities Limited have "Neutral" view about the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 10 | 3 | 2 | 0 | 0 |
% | 66.67 | 20.00 | 13.33 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Anand Rathi | Apply | |
Ashika Research | Apply | |
Axis Capital | Neutral | |
Capital Market | May Apply | |
Choice Equity Broking Pvt Ltd | Apply | |
Dilip Davda | May Apply | |
Dolat Analysis and Research | Apply | |
GEPL Capital Ltd | Apply | |
HDFC Securities Limited | Neutral | |
ICICI Direct | Apply | |
Investmentz Ltd | Apply | |
SMC Global | May Apply | |
Sushil Finance Ltd | Apply | |
InvestorGain.com | Apply | |
Ventura Securities Limited | Apply |
The Captial Market (CapitalMarket.com) rating for Glenmark Life Sciences IPO is 48. Their analysis recommends May subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 48 | May subscribe |
[Dilip Davda] Though this is a second public issue from Glenmark group after nearly two decades, it is encasing on the fancy of pharma segment amidst pandemic and hence the issue is fully priced discounting all near term positives. Considering the group's credentials and ongoing grey market activities the IPO may evoke a good response. Cash surplus investors may consider investing in this offer with a long term perspective. Read detail review...
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|